Smoking cessation: How compelling is the evidence? A review

Health Policy

Volumn 91, Issue SUPPL. 1, 2009, Pages

  Tønnesen, Philip ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bupropion; Cost effective; Counseling; Nicotine replacement products; Smoking cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; CANNABINOID 1 RECEPTOR ANTAGONIST; CLONIDINE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; NICQB; NORTRIPTYLINE; PLACEBO; RIMONABANT; TA NIC; UNCLASSIFIED DRUG; VARENICLINE;

ABNORMAL DREAMING; ACUPUNCTURE; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; GROUP THERAPY; HUMAN; HYPNOSIS; INSOMNIA; NAUSEA; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; RELAPSE; SEIZURE; SMOKING CESSATION; SOCIAL SUPPORT; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; PROCEDURES;

EVIDENCE-BASED MEDICINE; HUMANS; NICOTINE; SMOKING CESSATION;

EID: 69549153411     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8510(09)70004-1     Document Type: Article

References (64)

1. World Health Organization. International Classification of Diseases. 10th ed. (1992), WHO, Geneva
2. US Department of Health and Human Services. Nicotine addiction. A report of the Surgeon General (1998), US Department of Health and Human Services, Rockville, MD
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Association, Washington, DC
4. Watkins S.S., Koob G.F., and Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine and Tobacco Research 2 (2000) 19-37
5. Batra V., Patkar A.A., Berrettini W.H., Weinstein S.P., and Leone F.T. The genetic determinants of smoking. Chest 123 (2003) 1730-1739
6. Silagy C., Lancaster T., Stead L., Mant D., and Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews, Issue 1, 2006. Available at: http://www.cochrane.org/reviews/en/ab000146.html
7. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., et al., Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. Journal of the American Medical Association 296 (2006) 47-55
8. Fiore M.C., Bailey W.C., Cohen S.J., et al. Clinical Practice Guideline. Treating Tobacco use and Dependence: 2008 Update (May 2008), US Department of Health and Human Services. Public Health Service, Rockville, MD
9. West R., McNeill A., and Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 55 (2000) 987-999
10. Jorenby D.E., Hays J.T., Rigotti N.A., et al. Efficacy of varenicline, an a4, b2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. Journal of the American Medical Association 296 (2006) 56-63
11. Tonstad S., Tønnesen P., Hajek P., et al. Effect of maintenance therapy with varenicline on smoking cessation. Journal of the American Medical Association 296 (2006) 64-71
12. National Institute for Clinical Excellence (NICE). Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. National Institute for Clinical Excellence Technology Appraisal Guidance No. 39, Apr 2002. http://www.nice.org.uk
13. Anderson J.E., Jorneby D.E., Scott W.J., et al. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 121 3 (2002) 932-941
14. Hughes J.R., Fiester S., Goldstein M.G., Resnick M.P., Rock N., and Ziedonis D. The American Psychiatric Association Practice Guidelines for the treatment of patients with nicotine dependence. American Journal of Psychiatry 153 Suppl (1996) S1-31
15. Lancaster T., and Stead L.F. Self-help interventions for smoking cessation. The Cochrane Library Oxford: Update Software, 2002. Available at: http://www.cochrane.org/reviews
16. Borland R., Balmford J., and Hunt D. The effectiveness of personally tailored computer generated advice letters for smoking cessation. Addiction 99 (2004) 369-377
17. Aveyard P., Griffin C., Lawrence T., and Cheng K.K. A controlled trial of an expert system and self help manual interventions based on the stages of change versus standard help materials in smoking cessation. Addiction 98 (2003) 345-354
18. Lichtenstein E., Glasgow R.E., Lando H.A., Ossip-klein D.J., and Boles S.M. Telephone counseling for smoking cessation: rationales and meta-analytic review of evidence. Health Education Research 11 (1996) 243-257
19. Borland R., Segan C.J., Livingston P.M., and Owen N. The effectiveness of callback counselling for smoking cessation: a randomised trial. Addiction 96 (2001) 881-889
20. Macleod Z.R., Charles M.A., Arnaldi V.C., and Adams I.M. Telephone counselling as an adjunct to nicotine patches in smoking cessation: a randomised controlled trial. Medical Journal of Australia 179 (2003) 349-352
21. Stead L.F., Lancaster T., and Perera R. Telephone counselling for smoking cessation. Cochrane Database of Systematic Reviews (2003) CD002850.
22. Lancaster T., and Stead L. Physician advice for smoking cessation. Cochrane Database of Systematic Reviews 4 (2004 Oct 18) CD000165.
23. Rice V., and Stead L.F. Nursing interventions for smoking cessation. Cochrane Database of Systematic Reviews 1 (2004) CD001188.
24. Lancaster T., and Stead L.F. Individual behavioural counselling for smoking cessation. The Cochrane Library (2002), Update Software, Oxford
25. Stead L.F., and Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database of Systematic Reviews (2002) CD001007.
26. Hjalmarson A., Franzon M., Westin A., and Wiklund O. Effect of nicotine nasal spray on smoking cessation. Archives of Internal Medicine 154 (1994) 2567-2572
27. Hjalmarson A., Nilsson F., Sjostrom L., and Wiklund O. The nicotine inhaler in smoking cessation: a double-blind randomised clinical evaluation. Archives of Internal Medicine 157 (1997) 1721-1728
28. Hjalmarson A. Smoking Cessation. Evaluation of supportive strategies with special reference to nicotine replacement therapy, MSc Thesis. Gothenburg University; 1996.
29. Tønnessen P., Paoletti P., Gustavsson G., Russell M.A., Saracci R., Gulsvik A., et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE-trial. European Respiratory Journal 13 (1999) 238-246
30. Schmølker L. A review of the evidence for long-term use of Nicotine Replacement Therapy (NRT), Master thesis (30 June 2005), Det sundhedsvidenskabelige fakultet, University of Copenhagen, Copenhagen
31. Shiffman S., Rolf C.N., Hellebusch S., Gorsline J., Goroedtzky C.W., Chiang Y.K., et al. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction 97 (2002) 505-516
32. Cahill K., Stead L., and Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews Issue 1 (2007) 10.1002/14651858.CD006103.pub2 CD006103.
33. Hughes J.R., Stead L.F., and Lancaster T. Antidepressants for smoking cessation (Cochrane Review). The Cochrane Collaboration; Issue 1 (2002), Update Software, Oxford
34. Aubin J.H., Bobak A., Britton J.R., Oncken C., Billing C.B., Gong J., et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomized, open-label trial. Thorax 63 (2008) 717-724
35. Hurt R.D., Sachs D.P.L., Glover E.D., et al. A comparison of sustained release bupropion and placebo for smoking cessation. New England Journal of Medicine 337 (1997) 1120-1195
36. Tønnesen P., Tonstad S., Hjalmarson A., et al. A multicentre, randomised, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. Journal of Internal Medicine 254 (2003) 184-192
37. White A., Resch K., and Ernst E. A meta-analysis of acupuncture techniques for smoking cessation. Tobacco Control 8 (1999) 393-397
38. Yiming C., Changxin Z., Ung W.S., Lei Z., and Kean L.S. Laser acupuncture for adolescent smokers - a randomised, double-blind controlled trial. American Journal of Chinese Medicine 28 (2000) 443-449
39. Abbot N.C., Stead L.F., White A.R., Barnes J., and Ernst E. Hypnotherapy for smoking cessation. Cochrane Database of Systematic Reviews 2 (2000) CD001008.
40. Hajek P., and Stead L.F. Aversive smoking for smoking cessation. Cochrane Database of Systematic Reviews 3 (2004) CD000546.
41. Ussher M., West R., Taylor A.H., and McEwen A. Exercise interventions for smoking cessation. The Cochrane Library (2000), Update Software, Oxford
42. Doll R., Peto R., Boreham J., and Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. British Medical Journal 328 (2004) 1529-1533
43. Deaths from smoking in EU25 (European Union) 25 countries. Available at: http://www.deathsfromsmoking.net
44. 1. The Lung Health Study. Journal of the American Medical Association 272 (1994) 1497-1505
45. Anthonisen N.R., Skeans M.A., Wise R.A., Manfreda J., Kanner R.E., Connett J.E., and for the Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality. Annals of Internal Medicine 142 (2005) 233-239
46. Parrott S., Godfrey C., and Raw M. Costs of employee smoking in the workplace in Scotland. Tobacco Control 9 (2000) 187-192
47. Drummond M.F., O'Brien B.J., Stoddart G.L., and Torrance G.W. Methods for the economic evaluation of health care programmes. 2nd ed. (1997), Oxford University Press, Oxford 109-112
48. Gold M.R., Siegel J.E., Russel L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
49. Maynard A. Developing the health care market. The Economic Journal 101 (1991) 1277-1286
50. Parrott S., Godfrey C., Raw M., West R., and McNeill A. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Thorax 53 Suppl 5, Part 2 (1998) S1-38
51. Godfrey C. The economic and social costs of lung cancer and the economics of smoking prevention. Monaldi Archives for Chest Disease 56 (2001) 458-461
52. NHS Centre for Reviews & Dissemination. A rapid and systematic review of the clinical and cost effectiveness of bupropion SR and nicotine replacement therapy (NRT) for smoking cessation (February 2002), NHS Centre for Reviews & Dissemination, University of York, York
53. Schulmann K.A., Lorna A.L., Glick H.A., and Eisenberg J. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Annals of Internal Medicine 114 (1991) 798-802
54. Rutten-Van Mölken M.P.M.H., Van Doorslaer E., and Rutten F.F.H. Economic appraisal of asthma and COPD care: a literature review 1980-1981. Social Science & Medicine 35 (1992) 161-175
55. Cromwell J., Bartosch W.J., Fiore M.C., Hasselblad V., and Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. Journal of the American Medical Association 278 (1997) 1759-1766
56. Department of Health. Independent inquiry into inequalities in health (1998), Stationery Office, London
57. Anthonisen N.R., Connett J.E., and Murray R.P. Smoking and lung function of Lung Health Study participants after 11 years. American Journal of Respiratory and Critical Care Medicine 166 (2002) 675-679
58. LeSage M.G., Keyler D.E., and Pentel P.R. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. AAPS Journal 8 (2006) E65-E75. (hhtp://www.aapsj.org)
59. Hatsukami D.K., Rennard S., Jorgenby D., Fiore M., Koopmeiners, and De Vos A. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clinical Pharmacology & Therapeutics 78 (2005) 456-467
60. Cerny E.H., Levy R., Mauel M., Mpandi M., Muter M., Henzelin-Nkubana C., et al. Preclinical development of a vaccine "against smoking". Onkologie 25 (2002) 406-411
61. Cohen C., Kodas E., and Griebel G. CB(1) receptor antagonists for the treatment of nicotine addiction. Pharmacology Biochemistry and Behavior 81 (2005) 387-395
62. Flegal K.M., Troriano R.P., Pamuk E.R., Kuczmarski R.J., and Campbell S.M. The influence of smoking cessation on the prevalence of overweight in the United States. New England Journal of Medicine 333 (1995) 1165-1170
63. Cahill K., and Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database of Systematic Reviews 3 (2007) CD005353.
64. Avon J. Keeping science on top in drug evaluation. New England Journal of Medicine 357 (2007) 633-635